135 related articles for article (PubMed ID: 8180023)
1. Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate).
O'Rourke NP; McCloskey EV; Rosini S; Coleman RE; Kanis JA
Br J Cancer; 1994 May; 69(5):914-7. PubMed ID: 8180023
[TBL] [Abstract][Full Text] [Related]
2. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate.
O'Rourke NP; McCloskey EV; Vasikaran S; Eyres K; Fern D; Kanis JA
Br J Cancer; 1993 Mar; 67(3):560-3. PubMed ID: 8439504
[TBL] [Abstract][Full Text] [Related]
3. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
4. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
[TBL] [Abstract][Full Text] [Related]
5. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
Walls J; Ratcliffe WA; Howell A; Bundred NJ
Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
[TBL] [Abstract][Full Text] [Related]
6. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
[TBL] [Abstract][Full Text] [Related]
7. An audit of the management of malignant hypercalcaemia.
Gerrard GE; Dodwell DJ; Vail A; Watters J; Overend MA
Clin Oncol (R Coll Radiol); 1996; 8(1):39-42. PubMed ID: 8688360
[TBL] [Abstract][Full Text] [Related]
8. [Pamidronate in the treatment of tumor-associated hypercalcemia].
Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
[TBL] [Abstract][Full Text] [Related]
9. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia.
Dodwell DJ; Howell A; Morton AR; Daley-Yates PT; Hoggarth CR
Postgrad Med J; 1992 Jun; 68(800):434-9. PubMed ID: 1437922
[TBL] [Abstract][Full Text] [Related]
10. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.
Sawyer N; Newstead C; Drummond A; Cunningham J
Bone Miner; 1990 May; 9(2):121-8. PubMed ID: 2350615
[TBL] [Abstract][Full Text] [Related]
11. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
12. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
Ralston SH; Alzaid AA; Gardner MD; Boyle IT
Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513
[TBL] [Abstract][Full Text] [Related]
13. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
Coleman RE; Rubens RD
Br J Cancer; 1987 Oct; 56(4):465-9. PubMed ID: 3689664
[TBL] [Abstract][Full Text] [Related]
14. Tumour induced hypercalcaemia: a case for active treatment.
O'Rourke NP; McCloskey EV; Kanis JA
Clin Oncol (R Coll Radiol); 1994; 6(3):172-6. PubMed ID: 8086352
[TBL] [Abstract][Full Text] [Related]
15. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate.
Rizzoli R; Buchs B; Bonjour JP
Int J Cancer; 1992 Mar; 50(5):706-12. PubMed ID: 1531972
[TBL] [Abstract][Full Text] [Related]
16. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.
Davis JR; Heath DA
Br J Clin Pharmacol; 1989 Sep; 28(3):269-74. PubMed ID: 2789920
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia.
Ralston SH; Alzaid AA; Gallacher SJ; Gardner MD; Cowan RA; Boyle IT
Q J Med; 1988 Oct; 68(258):825-34. PubMed ID: 3268894
[TBL] [Abstract][Full Text] [Related]
18. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.
Gallacher SJ; Ralston SH; Dryburgh FJ; Logue FC; Allam BF; Boyce BF; Boyle IT
Postgrad Med J; 1990 Nov; 66(781):918-22. PubMed ID: 2267202
[TBL] [Abstract][Full Text] [Related]
19. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia.
Ostenstad B; Andersen OK
Acta Oncol; 1992; 31(8):861-4. PubMed ID: 1290634
[TBL] [Abstract][Full Text] [Related]
20. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy.
McIntyre HD; Cameron DP; Urquhart SM; Davies WE
Postgrad Med J; 1989 Apr; 65(762):244-6. PubMed ID: 2594602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
